ArticleDiscover oncology2026
Development and validation of an oxidative phosphorylation based prognostic model revealing tumor progression and immune microenvironment in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) remains a leading cause of cancer mortality worldwide. Although oxidative phosphorylation (OXPHOS) has been linked to tumor progression, its prognostic significance and underlying mechanisms in LUAD remain unclear.
methodsRNA-seq data from TCGA were used as the discovery cohort, and multiple GEO datasets were used for independent validation. OXPHOS-related genes were obtained from MitoCarta3.0. Prognostic biomarkers were selected by LASSO-Cox regression. Immune cell infiltration was estimated using CIBERSORT and ssGSEA. Single-cell RNA-seq data were analyzed to examine biomarker expression, pathway enrichment, and cell-cell communication.
resultsThirteen OXPHOS-associated genes were used to construct a prognostic model with robust predictive performance. Model performance was validated across independent cohorts and demonstrated reliable prognostic value. Higher risk scores correlated with poorer overall survival and reduced immune infiltration. UQCC3⁺ and RAB5IF⁺ epithelial cells were enriched in E2F target and G2M checkpoint pathways and showed enhanced interactions via TGF-β and Galectin signaling.
conclusionsWe present an OXPHOS-based prognostic model for LUAD. OXPHOS reprogramming, particularly involving UQCC3 and RAB5IF in epithelial cells, may promote malignant proliferation and immunosuppression. These findings provide novel prognostic biomarkers and potential therapeutic targets, which may support personalized treatment strategies and guide future translational studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.